GLP-1 Pills vs Injections: Cost, Results and Trade-Offs

If you're considering a GLP-1 medication for weight loss, the choice is no longer simply between taking an injection or not taking one. In 2026, there are FDA-approved oral options, including daily semaglutide tablets and orforglipron (Foundayo), alongside the injectable GLP-1 medications that have been available for years.

That gives you more options, but it also makes the decision more complicated.

A pill may sound easier if you don't like needles. An injection may be simpler if you don't want to take a medication every day. Then there's the question of cost, which can vary substantially depending on the drug, dose, insurance coverage, and whether you're paying cash.

The results matter too. Clinical trials show meaningful weight loss with both oral and injectable GLP-1 medications, but the numbers come from different studies and shouldn't be treated as a direct head-to-head comparison.

TL;DR: Key Takeaways

• GLP-1 medications are now available as both pills and injections for certain weight-management uses.
• Wegovy (semaglutide) is available as both a once-weekly injection and a daily tablet in the United States.
• Foundayo (orforglipron) is a once-daily oral GLP-1 approved by the FDA in April 2026 for adults with obesity or overweight plus a weight-related medical condition.
• Clinical trials have shown substantial weight loss with oral semaglutide, orforglipron, and injectable semaglutide, but the trials used different populations, doses, and study designs.
• In 2026, self-pay prices for the Wegovy pill start at $149 per month, while Wegovy injection self-pay pricing starts at $349 per month. Foundayo self-pay pricing also starts at $149 per month.
• Pills avoid injections, but some oral GLP-1 medicines have specific dosing instructions. Foundayo is different because it can be taken at any time of day without food or water restrictions.
• Both pills and injections can cause gastrointestinal side effects such as nausea, diarrhea, constipation, and vomiting.

Have questions about GLP-1 medications for weight loss? Book a $39 online urgent care visit with August AI. A US-licensed clinician can review your health history and discuss whether a GLP-1 medication is appropriate for you, with same-day pharmacy pickup available across all 50 states when clinically appropriate.

The visit does not guarantee a prescription. Long-term GLP-1 weight management is typically better handled by your primary care provider or an endocrinologist who can monitor progress, adjust dosing, and coordinate other care. August online urgent care doesn't prescribe compounded or non-FDA-approved GLP-1 products.

What's the difference between a GLP-1 pill and an injection?

Both forms work through the GLP-1 pathway, which helps regulate appetite, food intake, and blood sugar.

The biggest practical difference is how you take them.

Injectable medications like Wegovy (semaglutide) are administered under the skin, usually once a week. You don't have to remember a pill every day.

Oral medications are taken daily. In 2026, the two main options are oral semaglutide sold as Wegovy tablets and orforglipron sold as Foundayo.

The Wegovy tablet contains semaglutide, the same active ingredient as the injectable version. The FDA's prescribing information includes instructions for switching between the 25 mg tablet and the 2.4 mg injection, though the dosing schedules aren't identical.

Foundayo contains orforglipron, a different GLP-1 receptor agonist. Unlike oral semaglutide, Foundayo doesn't require food or water restrictions around the dose.

Oral GLP-1 pill options in 2026

The phrase "oral GLP-1 pill" now covers more than one medication.

Wegovy tablets

Wegovy tablets contain semaglutide and are available in 1.5 mg, 4 mg, 9 mg, and 25 mg tablets. The 25 mg tablet is the higher-dose tablet used for weight reduction.

The tablet is taken once daily. Oral semaglutide has demonstrated significant weight loss in clinical trials. In the OASIS 4 trial, people with overweight or obesity who took 25 mg of oral semaglutide had an estimated average weight change of 13.6% at week 64, compared with 2.2% with placebo. Gastrointestinal side effects were common, occurring in 74% of people taking oral semaglutide compared with 42.2% taking placebo.

Foundayo (orforglipron)

Foundayo is a once-daily oral GLP-1 medication approved by the FDA in April 2026 for adults with obesity or adults who are overweight and have at least one weight-related medical condition.

One practical difference is how it's taken. Foundayo can be taken at any time of day without food or water restrictions.

In a large 72-week trial of adults with obesity who didn't have diabetes, average weight loss ranged from 7.5% to 11.2% depending on the orforglipron dose, compared with 2.1% with placebo. At the highest dose studied, 54.6% of participants lost at least 10% of their body weight.

Those numbers are useful for understanding the potential effect of the drug, but they shouldn't be used to say that orforglipron produces exactly the same results as oral or injectable semaglutide. The medications were studied in different trials with different designs and patient populations.

How do pills compare with GLP-1 injections for weight loss?

Injectable semaglutide has been studied extensively for weight management.

In the large STEP 1 trial, adults with overweight or obesity who received once-weekly injectable semaglutide 2.4 mg lost an average of about 15% of their starting body weight after 68 weeks, compared with about 2.4% with placebo.

Oral semaglutide has also produced substantial weight loss. In OASIS 4, the 25 mg tablet produced an estimated average weight reduction of 13.6% at week 64.

Orforglipron produced average weight reductions of up to 11.2% at 72 weeks in the large obesity trial.

At first glance, you could put those percentages next to each other and assume the injection produces more weight loss than the pills. That would be too simple.

These weren't head-to-head trials. Participants were different, treatment periods were different, and the doses and study designs were different. Individual responses also vary considerably.

The more useful takeaway is that both oral and injectable GLP-1 medications can produce clinically meaningful weight loss when used in appropriate patients alongside diet and physical activity.

Wegovy pill cost vs injection cost

Cost is one of the biggest practical differences to consider.

As of 2026, Novo Nordisk's published self-pay pricing lists the Wegovy pill at:

These are manufacturer-published self-pay prices, and offers can have eligibility requirements or expiration dates. Insurance pricing can be very different.

So if you're specifically searching for the Wegovy pill cost, the answer in 2026 isn't one fixed number. The published self-pay price depends on the tablet strength and current offer.

Insurance can change the calculation even more. A medication with a higher cash price may cost less out of pocket for someone whose insurance covers it, while someone without coverage may pay the full self-pay price.

What does Foundayo cost?

Foundayo is another oral GLP-1 option to consider when looking at GLP-1 cost in 2026.

Lilly currently lists self-pay pricing starting at $149 per month. Published prices vary by dose, with current self-pay prices ranging from $149 to $349 per month. Certain doses have temporary savings offers through December 31, 2026.

Eligible people with commercial insurance may qualify to pay as little as $25 per month through Lilly's savings program, though eligibility requirements apply.

That doesn't mean Foundayo will cost every patient $149 or $25. Your actual cost depends on insurance, eligibility, dose, pharmacy, and the specific savings program available to you.

Orforglipron vs semaglutide: are they the same?

No.

Orforglipron and semaglutide both work on the GLP-1 receptor, but they're different medications.

Semaglutide is the active ingredient in Wegovy. It's available as an injection and, now, as a tablet for certain uses.

Orforglipron is the active ingredient in Foundayo. It's an oral small-molecule GLP-1 receptor agonist.

There are some head-to-head data between orforglipron and oral semaglutide, but an important limitation is that the comparison was studied in people with type 2 diabetes, not as a direct weight-loss comparison between the currently approved obesity doses.

In Lilly's ACHIEVE-3 trial, orforglipron 17.2 mg produced greater reductions in A1C and body weight than oral semaglutide 14 mg in adults with type 2 diabetes. These results were reported by Lilly, which sponsored the trial.

That study can help explain how the two drugs compare in diabetes treatment, but it shouldn't be turned into a claim that one medication will produce a specific amount of weight loss for every person.

Pills vs injections: the everyday trade-offs

Pills may make sense if you want to avoid injections

Some people simply don't want to inject medication into their skin. An oral GLP-1 removes that part of treatment.

But a pill isn't automatically easier. Daily medication requires remembering a dose every day. Some oral semaglutide regimens have specific instructions around taking the medication, while Foundayo can be taken without food or water restrictions.

Injections may mean less frequent dosing

Wegovy injection is taken once weekly.

For someone who struggles to remember daily medications, a weekly injection may fit more easily into their routine. It also avoids the absorption issues that come with taking a medication by mouth. The trade-off is having to administer the injection.

Side effects can happen with both

Nausea, diarrhea, constipation, vomiting, abdominal discomfort, and other digestive symptoms are among the side effects reported with GLP-1 medications.

For Foundayo, gastrointestinal reactions occurred in 60% to 69% of participants across the studied doses compared with 37% with placebo.

The Wegovy prescribing information also contains important warnings and contraindications, including a boxed warning related to thyroid C-cell tumors based on findings in rodents, as well as warnings concerning pancreatitis, gallbladder disease, kidney injury related to dehydration, and serious gastrointestinal reactions.

These medications aren't appropriate for everyone, and a clinician should review your medical history before prescribing one.

What about compounded GLP-1 pills or injections?

Price comparisons can get confusing when compounded products are included.

Compounded semaglutide and other non-FDA-approved GLP-1 products may be advertised at lower prices than branded medications. But FDA approval and compounding aren't the same thing.

The FDA says compounded GLP-1 drugs aren't FDA-approved and therefore aren't reviewed by the agency for safety, effectiveness, and quality before being marketed. The agency has also reported concerns involving dosing errors and fraudulent compounded products.

A lower advertised price doesn't tell you whether a medication is appropriate for you or whether it's an FDA-approved product.

So which GLP-1 form should you discuss with your clinician?

There's no single pill-versus-injection answer that works for everyone.

The decision can depend on your weight-management goals, medical history, other medications, insurance coverage, budget, dosing preferences, and how comfortable you are with injections.

If you're comparing an oral GLP-1 pill with an injection, ask about four things:

1. Expected benefit: What amount of weight loss is realistic for someone with your medical history?
2. Cost: What will you actually pay each month after insurance or manufacturer savings?
3. Dosing: Would a daily pill or weekly injection fit your routine better?
4. Safety: Do you have any medical conditions or take medications that affect which GLP-1 treatment is appropriate?

You can also compare the medication cost with the cost of the medical visits, labs, and follow-up that may be needed during treatment.

Conclusion

The arrival of oral GLP-1 medications gives people another way to approach weight management without a weekly injection. In 2026, the main oral options include Wegovy tablets containing semaglutide and Foundayo containing orforglipron.

The cost difference can be meaningful, particularly for people paying out of pocket. But price is only one part of the decision. The dosing schedule, side effects, medical history, insurance coverage, and expected response all matter.

And while clinical trials show impressive results for both pills and injections, the studies aren't interchangeable. A percentage from one trial doesn't predict exactly what another person will lose on a different GLP-1 medication.

The right comparison is less about whether pills or injections are universally better and more about which approved treatment, dose, and payment option fits your medical situation and your ability to stay on treatment consistently.